drugset / Trial / NCT06168851
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
Phase 2
Recruiting
60 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Beijing Children's Hospital · collabTianjin Children's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.
Timeline
- Start
- 2023-12-28
- Primary completion
- 2025-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD38 antibody | Monoclonal antibody | 16 mg/kg | Intravenous |